Skip to main content

Table 2 The relationship of expression levels of SOX21 and SOX21-AS1 with clinicopathologic data of OSCC patients

From: Aberrant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer

Variables

SOX21 (n = 86)

SOX21-AS1 (n = 86)

Low expression

High expression

P value

Low expression

High expression

P value

Number (%)

Number (%)

Number (%)

Number (%)

Sex

 Female

5 (55.6)

4 (44.4)

1.000a

2 (22.2)

7 (77.8)

0.712a

 Male

38 (49.4)

39 (50.6)

27 (35.1)

50 (64.9)

Age

 ≤50

12 (54.5)

10 (45.5)

0.621b

8 (36.4)

14 (63.6)

0.761b

 >50

31 (48.4)

33 (51.6)

21 (32.8)

43 (67.2)

Cancer location

 Buccal and other oral mucosal sites

36 (54.5)

30 (45.5)

0.126b

25 (37.9)

41 (62.1)

0.138b

 Tongue

7 (35.0)

13 (65.0)

 

4 (20.0)

16 (80.0)

Cell differentiation

 Well

5 (41.7)

7 (58.3)

0.534b

4 (33.3)

8 (66.7)

1.000a

 Moderate, poor

38 (51.4)

36 (48.6)

25 (33.8)

49 (66.2)

AJCC pathological stage

 I

6 (37.5)

10 (62.5)

0.268b

2 (12.5)

14 (87.5)

0.047 b

 II, III, IV

37 (52.9)

33 (47.1)

27 (38.6)

43 (61.4)

T classification

 T1

6 (35.3)

11 (64.7)

0.176b

2 (11.8)

15 (88.2)

0.033 b

 T2, T3, T4

37 (53.6)

32 (46.4)

27 (39.1)

42 (60.9)

N classification

 N0

32 (50.0)

32 (50.0)

1.000b

20 (31.2)

44 (68.8)

0.683b

 N1, N2

11 (50.0)

11 (50.0)

9 (40.9)

13 (59.1)

  1. The italic indicated p value <0.05
  2. a P value was estimated by Fisher’s exact test
  3. b P value was estimated by chi-square test